Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Consensus Price Target from Brokerages
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) have been given a consensus recommendation of “Buy” by the six research firms that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The […]
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) have been given a consensus recommendation of “Buy” by the six research firms that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The […]
